X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (46) 46
index medicus (44) 44
microbiology (33) 33
genotype (30) 30
gastroenterology & hepatology (28) 28
hepacivirus - genetics (28) 28
male (27) 27
hepatitis c virus (26) 26
antiviral agents - therapeutic use (25) 25
female (25) 25
hepatitis c (25) 25
hepatitis c, chronic - drug therapy (25) 25
beer (24) 24
biochemistry (24) 24
chemistry (24) 24
compositions thereof (24) 24
culture media (24) 24
enzymology (24) 24
metallurgy (24) 24
microorganisms or enzymes (24) 24
mutation or genetic engineering (24) 24
propagating, preserving or maintaining microorganisms (24) 24
sofosbuvir (24) 24
spirits (24) 24
vinegar (24) 24
wine (24) 24
general tagging of cross-sectional technologies spanning over several sections of the ipc (23) 23
general tagging of new technological developments (23) 23
human necessities (23) 23
hygiene (23) 23
medical or veterinary science (23) 23
middle aged (23) 23
preparations for medical, dental, or toilet purposes (23) 23
technical subjects covered by former uspc cross-reference art collections [xracs] and digests (23) 23
technologies for adaptation to climate change (23) 23
technologies or applications for mitigation or adaptation againstclimate change (23) 23
investigating or analysing materials by determining theirchemical or physical properties (22) 22
measuring (22) 22
organic chemistry (22) 22
peptides (22) 22
physics (22) 22
testing (22) 22
heterocyclic compounds (21) 21
ribavirin (21) 21
hcv (20) 20
hepatitis (20) 20
hepacivirus - drug effects (19) 19
adult (17) 17
aged (17) 17
drug therapy, combination (17) 17
treatment outcome (17) 17
gastroenterology and hepatology (16) 16
uridine monophosphate - analogs & derivatives (16) 16
genotype & phenotype (15) 15
genotypes (15) 15
hepatitis c, chronic - virology (15) 15
patients (15) 15
abridged index medicus (14) 14
antiviral agents - adverse effects (14) 14
health aspects (14) 14
specific therapeutic activity of chemical compounds ormedicinal preparations (14) 14
care and treatment (13) 13
virology (13) 13
benzimidazoles - therapeutic use (12) 12
cirrhosis (12) 12
fluorenes - therapeutic use (12) 12
infectious diseases (12) 12
sofosbuvir - therapeutic use (12) 12
antiviral agents (11) 11
clinical trials (11) 11
drug resistance, viral (11) 11
hepatitis-c virus (11) 11
interferon (11) 11
resistance (11) 11
uridine monophosphate - therapeutic use (11) 11
direct-acting antivirals (10) 10
pharmacology & pharmacy (10) 10
therapy (10) 10
velpatasvir (10) 10
viral nonstructural proteins - antagonists & inhibitors (10) 10
antiretroviral drugs (9) 9
infections (9) 9
ledipasvir (9) 9
liver cirrhosis (9) 9
plus ribavirin (9) 9
ribavirin - therapeutic use (9) 9
animals (8) 8
antiviral agents - pharmacology (8) 8
benzimidazoles - adverse effects (8) 8
drug combinations (8) 8
drug therapy (8) 8
fluorenes - adverse effects (8) 8
genetic aspects (8) 8
hepatitis c - drug therapy (8) 8
in-vitro (8) 8
infection (8) 8
replication (8) 8
sofosbuvir - adverse effects (8) 8
treatment-naive (8) 8
uridine monophosphate - adverse effects (8) 8
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Infectious Diseases, The, ISSN 1473-3099, 2016, Volume 16, Issue 6, pp. 685 - 697
Journal Article
Journal Article
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9883, pp. 2100 - 2107
Journal Article
Journal Article
Journal of Viral Hepatitis, ISSN 1352-0504, 11/2014, Volume 21, Issue 11, pp. 762 - 768
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 16, pp. 1483 - 1493
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2015, Volume 373, Issue 27, pp. 2608 - 2617
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 705 - 713
Among patients coinfected with HIV-1 and HCV genotype 1 or 4 who were receiving effective antiretroviral therapy, treatment with 12 weeks of ledipasvir and... 
MEDICINE, GENERAL & INTERNAL | HEPATOCELLULAR-CARCINOMA | INTERFERON | THERAPY | HEPATITIS-C VIRUS | CIRRHOSIS | ALPHA-2A PLUS RIBAVIRIN | VETERANS | GENOTYPE 1 INFECTION | COHORT | LIVER-DISEASE | HIV-1 | Humans | Middle Aged | Drug Resistance, Viral | Fluorenes - therapeutic use | Hepacivirus - genetics | Male | RNA, Viral - blood | Hepatitis C, Chronic - complications | Viral Load | Female | Fluorenes - adverse effects | Uridine Monophosphate - adverse effects | Benzimidazoles - adverse effects | Drug Therapy, Combination | Benzimidazoles - therapeutic use | Uridine Monophosphate - therapeutic use | Hepacivirus - drug effects | Fluorenes - pharmacokinetics | Hepacivirus - isolation & purification | Anti-Retroviral Agents - therapeutic use | Antiviral Agents - therapeutic use | Benzimidazoles - pharmacokinetics | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - adverse effects | Uridine Monophosphate - analogs & derivatives | HIV Infections - complications | HIV Infections - drug therapy | Uridine Monophosphate - pharmacokinetics | Sofosbuvir | Care and treatment | Research | Hepatitis C virus | HIV infection | Emtricitabine | Headache | Antiretroviral drugs | Inhibitor drugs | Diarrhea | Fatigue | Patients | Efavirenz | Studies | Tenofovir | Cirrhosis | Genotype & phenotype | Hepatitis | Human immunodeficiency virus--HIV | Hepatitis C | Drug therapy | Genotypes
Journal Article